Tandem Diabetes Care received FDA approval in December 2019 for Control-IQ, a closed-loop technology that uses Tandem's t:slim X2 insulin pump and the Dexcom G6 to "to automatically increase, decrease, or stop the delivery of insulin in response to the glucose levels of people with Type 1 diabetes."[20] Dexcom entered into a partnership with Livongo, a digital chronic care management company, in January 2020 to share CGM data from the Dexcom G6 with Livongo’s platform.[21] This integration will allow Livongo to incorporate the CGM data along with other patient data to provide health insights based on its algorithm to help patients manage their diabetes.[22] In February 2020, Dexcom and Insulet Corporation signed a non-exclusive, global agreement to combine current and future Dexcom continuous glucose monitoring systems with Insulet’s tubeless insulin delivery Pod into the Omnipod Horizon™ System for automated insulin delivery.[23] This will give the ability to adjust insulin doses based on Insulet’s algorithm or through their smartphone.[24] The company also announced in March 2020 a partnership with Welldoc to integrate G6 CGM data with BlueStar, a digital platform for diabetes management.[25] BlueStar will combine the CGM data with information on patients' activity, nutrition, sleep and other factors to help them manage their condition.